Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)

T. Y. Seiwert, C. C. Foster, E. A. Blair, T. G. Karrison, N. Agrawal, J. M. Melotek, L. Portugal, R. J. Brisson, A. Dekker, S. Kochanny, Z. Gooi, M. W. Lingen, V. M. Villaflor, D. T. Ginat, D. J. Haraf, E. E. Vokes

Research output: Contribution to journalComment/debate

5 Scopus citations

Abstract

In the original article, the wrong supplementary material was accidentally uploaded. This has now been corrected. The Publisher apologizes for the error.

Original languageEnglish (US)
Number of pages1
JournalAnnals of Oncology
Volume30
Issue number10
DOIs
StatePublished - Oct 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522)'. Together they form a unique fingerprint.

  • Cite this

    Seiwert, T. Y., Foster, C. C., Blair, E. A., Karrison, T. G., Agrawal, N., Melotek, J. M., Portugal, L., Brisson, R. J., Dekker, A., Kochanny, S., Gooi, Z., Lingen, M. W., Villaflor, V. M., Ginat, D. T., Haraf, D. J., & Vokes, E. E. (2019). Erratum: ERRATUM: OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer (Ann Oncol (2019) DOI: 10.1093/annonc/mdy522). Annals of Oncology, 30(10). https://doi.org/10.1093/annonc/mdz171